Apogee Therapeutics (APGE) stock is soaring 5.28% in Tuesday's trading session, buoyed by a positive analyst report from Mizuho Securities. The surge comes as investors react to the reaffirmation of a bullish outlook for the biopharmaceutical company.

Mizuho Securities analyst Joseph Catanzaro maintained a Buy rating on Apogee Therapeutics, setting an ambitious price target of $105.00. This target suggests significant upside potential from the stock's current trading levels, igniting investor enthusiasm and driving the sharp uptick in share price.

The maintained Buy rating and high price target indicate Mizuho's confidence in Apogee Therapeutics' future prospects. While specific details of Catanzaro's analysis were not provided, such bullish sentiment from a reputable financial institution often signals strong fundamentals or promising developments within the company. As the biopharmaceutical sector continues to attract attention, Apogee Therapeutics appears well-positioned to capitalize on industry trends, according to this latest analyst assessment.